Please use this identifier to cite or link to this item:
Title: Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
Filiation: Hospital Universitario de Fuenlabrada. Servicio de Oncología Médica
Mesh: Biomarkers
Lung Neoplasms
Issue Date: 5-Jul-2022
Publisher: Springer Science and Business Media LLC
Citation: BMC Cancer.2022 Jul;(22)1:732
Abstract: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain.
PMID: 35790916
Rights: info:eu-repo/semantics/openAccess
Atribución 3.0 España
ISSN: 1471-2407
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
Provencio-2022-Determination-of-essential-biomarke.pdf839.28 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons